Trials / Completed
CompletedNCT03766646
Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
Preoxygenation With High Flow Nasal Oxygenation Using Optiflow - Does Speech Have an Effect on The End Tidal Oxygen Achieved When Compared to Closed Mouth Nasal Breathing?
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- University Hospital Southampton NHS Foundation Trust · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
Detailed description
This is a randomised controlled trial on 34 patients undergoing routine elective surgery at the Princess Anne Hospital, Southampton. The study will take place from September 2018 to January 2019 and involve preoxygenating all participants for three minutes using the Optiflow™ device. During this time, participants will be instructed to either read aloud a standardised text or to breathe through their nose with a closed mouth. At the end of 3 minutes, the primary outcome, ETO2, will be measured and recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Optiflow | 45l.min oxygen |
Timeline
- Start date
- 2018-10-18
- Primary completion
- 2018-11-16
- Completion
- 2018-11-16
- First posted
- 2018-12-06
- Last updated
- 2020-10-30
- Results posted
- 2020-10-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03766646. Inclusion in this directory is not an endorsement.